This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each Rl is an anionic group, L is a linker and R2BF3 is - N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
这项披露涉及包含带有带正负电荷的三
氟硼酸酯假体基团的新型化合物,其靶向前列腺特异性膜抗原(PSMA),例如在前列腺癌中。这些化合物具有式I,其中每个Rl是一个阴离子基团,L是一个连接基团,R2 是-N(R3)2CH2 ,一个取代有
BF3或甲基 的
吡啶基团,或取代有甲基 的唑基团。还披露了用于成像和治疗表达PSMA的癌症的方法和用途。